InvestorsHub Logo
Followers 230
Posts 21491
Boards Moderated 2
Alias Born 08/03/2006

Re: 02opida post# 9346

Monday, 11/08/2021 8:15:01 AM

Monday, November 08, 2021 8:15:01 AM

Post# of 9772
Moving forward!!! This is great!

Message in reply to:

PRINCETON, N.J., Nov. 8, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has been granted a Pediatric Investigation Plan (PIP) product-specific waiver from the Medicines and Healthcare products Regulatory Agency (MHRA) for HyBryte™ (SGX301 or synthetic hypericin), which has successfully concluded a Phase 3 pivotal clinical study for the treatment of early stage cutaneous T-cell lymphoma (CTCL).



https://finance.yahoo.com/news/soligenix-granted-pediatric-investigational-plan-123000309.html


Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?

"We hope not." Richard Dennis

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNGX News